SELLAS Life Sciences (SLS) Cash & Equivalents Growth (1y) (2011 - 2026)

SELLAS Life Sciences (SLS) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 SELLAS Life Sciences 1.89 Bn 1.78 Bn - 107,000.00%

Historic Data

Download Data
DateValue
Mar 31, 2026 107,000.00%
Dec 31, 2025 -99.28%
Sep 30, 2025 110.64%
Jun 30, 2025 177.99%
Mar 31, 2025 0.00%
Dec 31, 2024 13,786.00%
Sep 30, 2024 425.78%
Jun 30, 2024 9,000.00%
Mar 31, 2024 -99.58%
Dec 31, 2023 -99.42%
Sep 30, 2023 3,900.00%
Jun 30, 2023 0.00%
Mar 31, 2023 23,802.00%
Dec 31, 2022 17,025.00%
Sep 30, 2022 -99.62%
Jun 30, 2022 0.00%
Mar 31, 2022 0.00%
Dec 31, 2021 0.00%
Sep 30, 2021 220.50%
Jun 30, 2021 -97.01%